Trial Profile
A Retrospective Cohort Study of Infusion Reactions Due to Vectibix.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 Nov 2013
Price :
$35
*
At a glance
- Drugs Panitumumab (Primary)
- Indications Cancer
- Focus Adverse reactions
- 08 Jun 2012 Planned End Date changed from 1 Mar 2011 to 1 Mar 2013 as reported by ClinicalTrials.gov.
- 30 Dec 2010 Additional lead trial investigator (Peacock N) added as reported by ClinicalTrials.gov.
- 12 Jul 2010 New trial record